ADA and Crohn disease: Additionally, drug persistence was significantly higher in Crohn's disease (CD) patients (<i>P</i> = .012), in the group of patients co-treated with immunomodulators (IMM) (<i>P</i> = .001) and in patients with post-induction (at week 8) ADA levels ≥ 7 μg/mL (<i>P</i> = .002).